Peter Adamson of GSK to Speak at 5th Ocular Diseases Conference Mar 21-22, 2013

Printer-friendly versionPDF version

Peter Adamson, Vice President and Head of Research and Ophthalmology at GlaxoSmithKline To Give a Featured Presentation at the 5th Ocular Diseases & Drug Development Conference (March 21-22, 2013 in San Francisco, CA)

San Francisco, CA, USA., January 10, 2013 - (PressReleasePoint) - Peter Adamson, Vice President and Head of Research and Ophthalmology at GlaxoSmithKline will give a featured presentation on “Lipoprotein-associated Phospholipase A2 Inhibition Regulates Retinal Vasopermeability During Experimental Diabetes” at GTCs 5th Ocular Diseases and Drug Development Conference to be held in San Francisco, CA on March 21-22, 2013.
 
In his presentation, Dr. Adamson will present data that indicates the inhibition of Lp-PLA2 in a preclinical model of hyperglycemia induced retinal vascular leak can prevent breakdown of the inner BRB. Lp-PLA2 may thus be a useful target for treatment of diabetic macular edema (DME).

Benefits of his presentation include:
1. Understanding pre-clinical models of hyperglycemia-induced retinal vascular permeability
2. Treatment for DME
3. Role of inflammation in DME
4. Blood-brain barrier vs Blood-retinal barriers
 
Pete Adamson first joined GSK in 2004 as Head of Cellular Pharmacology within the Atherosclerosis group. He later transitioned into the GSK Centre of Excellence in External Drug Discovery (CEEDD) where he was responsible for inflammation and ophthalmology opportunities. Pete briefly joined Ophthaltec as CEO before taking up his appointment with Ophthiris in 2008. During his time with GSK Pete has been responsible for the progression of a number of high profile external alliances and the development of a number of internal assets which are currently undergoing clinical assessment in ophthalmology
 
GTC’s 5th Ocular Diseases and Drug Development Conference promotes the discovery of ocular disease drug development by bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research and discovery, safety assessment, and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other eye diseases. The last annual conference was well attended by key R&D delegates GSK, Pfizer, B&L, Allergan and Alcon, and this year’s conference promises to be even bigger and better.
 
For more information, please visit www.gtcbio.com